Ifowem 2gm Injection Combipack contains Mesna (100mg) and Ifosfamide (2gm), formulated for intravenous administration in oncology settings. Ifosfamide is an alkylating agent used primarily in the treatment of various malignancies, including sarcomas, lymphomas, and testicular cancer, by interfering with DNA replication and inducing cytotoxicity in rapidly dividing cancer cells. Mesna serves as a uroprotective agent, administered concurrently to prevent hemorrhagic cystitis, a common adverse effect caused by the toxic metabolites of Ifosfamide. The combination ensures effective chemotherapeutic action while mitigating urothelial toxicity. Ifowem 2gm Injection Combipack is indicated for patients requiring Ifosfamide-based chemotherapy regimens, particularly when high doses increase the risk of bladder toxicity. Dosage and administration should be individualized based on the type and stage of cancer, patient condition, and renal function. Close monitoring of hematologic parameters, renal function, and hydration status is essential during therapy. Adverse reactions may include myelosuppression, nausea, vomiting, neurotoxicity, and potential nephrotoxicity. Mesna’s protective effect significantly reduces the incidence of hemorrhagic cystitis, improving patient tolerability. This combipack provides a convenient and effective means of delivering Ifosfamide with appropriate uroprotection, optimizing therapeutic outcomes in oncologic treatment protocols.